Chemcon Speciality Chemicals Ltd

- No current plans for raising debt for the upcoming capex, as the company expects internal accruals to sufficiently fund the next two years of expansion. - The company has already utilized ₹11 Crores from IPO proceeds for expansion, with the balance capex funded through internal accruals. - Chemcon has enhanced working capital requirements funded partly through IPO proceeds and internal sources. - There is no indication of any new fundraising through equity or debt mentioned in the transcript for the near future.

- Total capex planned over next two years is approximately Rs. 41 Crores (as per IPO proceeds). - Around Rs. 38 Crores already spent, including Rs. 12.62 Crores for additional land acquired last year. - Rs. 11 Crores utilized from IPO proceeds; remaining from internal accruals. - Expansion includes multipurpose facilities P8 and P9, enabling flexibility to add new and existing products. - Enough approved land and capital available for future plants P10 and P11. - Future expansions primarily funded through internal accruals; no debt anticipated for capex. - Additional capex aims to increase production capacity, especially for CMIC and HMDS products, targeting import substitution and new product basket. - Working capital requirement also a focus, with around Rs. 40 Crores invested for this purpose.

- Chemcon aims to increase production of HMDS from about 3000 tons to 3300 tons in the current financial year to address a domestic gap of 2000 tons (Page 12, 13). - Expansion projects P8 and P9 are expected to be operational by September and December respectively, adding capacity, especially for CMIC, with about 50% utilization expected in H2 for P8 and Q4 for P9 (Pages 10-11). - The company targets substitution of imports with increased domestic production, leveraging its technical edge and client acceptance (Page 13). - Bromide business volumes were down to Rs.30 Crores but expected to improve with crude prices near $70, indicating better mobilization and volumes in FY2022 though price pressure remains (Pages 5, 15). - New product additions and capacity expansions (Plant 10 and 11) are planned over next 2-5 years to reduce product concentration and diversify revenue streams (Page 14). - Overall, volumes and revenues are expected to grow via capacity expansions, import substitution, and new market penetration.

- Chemcon expects robust growth driven by increased production and capacity expansion, especially in HMDS and CMIC segments. - Expansion projects P8 and P9 targeted to be operational by September and December, respectively, adding new product capacities and flexibility. - The company anticipates better utilization of existing plants, with gradual ramp-up expected for new plants (e.g., 50% utilization for P8 in H2 and Q4 for P9). - Growth in the bromide business is expected due to recovery in crude prices and improved project mobilizations. - Margins are managed on a per kg basis rather than percentage, with a goal to maintain healthy profit levels despite raw material price fluctuations. - Working capital requirements may be stretched due to longer debtor days, but increased volumes and IPO funds are expected to support operations. - No debt is forecasted for future capex; expansions will be funded via internal accruals. - The company foresees revenue growth from import substitution and new product additions over the next 2-5 years.

From the transcript on page 16 of Chemcon Speciality Chemicals Limited's earnings call dated June 2, 2021, there is no explicit mention of the current or expected order book or pending orders. However, key related insights include: - Capacity utilization for CMIC is fully engaged currently; some flexibility exists to convert part of P6 for an additional 600 tons capacity pre-P8 commissioning. - Post commissioning of P8, CMIC capacity is expected to increase to about 3000 tons. - HMDS production is targeted to increase from 3000 tons to 3300 tons in FY2022. - The company is confident of catering to import substitution opportunities, particularly for HMDS, which has a domestic demand-supply gap. - Expansion projects P8 and P9 are expected operational by end of September and December 2021 respectively, contributing additional business and revenue. The discussion reflects strong demand and utilization but does not specify explicit order book figures.